Clinical trial
Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and…
NCT00035932 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00035932 |
|---|---|
| Title | Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV |
| Official title | Phase III Open Label Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Atazanavir + ritonavir + tenofovir + nucleoside, Atazanavir + saquinavir + tenofovir + nucleoside, Lopinavir/ritonavir + tenofovir + nucleoside |
| Enrollment | 571 |
| Start date | Nov 1, 2001 |
| Primary completion | Jul 1, 2003 |
| Completion | Mar 1, 2009 |
| First posted | May 8, 2002 |
| Last update posted | Dec 24, 2010 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: